PubMed Health⌕ Search

Biomedical subjects

T Taiminen

Publications and source records attributed to T Taiminen.

25 records · Page 2Linked to original sources
PubMed1996

Prediction of positive placebo response among chronic schizophrenic outpatients.

We undertook this study to determine whether predictors of positive placebo response in chronic schizophrenic outpatients could be identified. Twelve placebo responders and 33 placebo nonresponders who participated in a parallel-group, double-blind, 12-week clinical drug trial were compared. No significant differences between the groups were found with regard to 16 anamnestic and symptom variables. To investigate further which variables at baseline predicted positive placebo response, a stepwise linear regression model was created. Of the seven variables entered into the model, only high scores in the positive domain of the Positive and Negative Syndrome Scale (delusions, unusual thought content, grandiosity, and suspiciousness/persecution) at baseline predicted significantly positive placebo response (p = .0047). Because the onset of placebo response was gradual, the authors hypothesize that placebo response in chronic schizophrenia consists mainly of two ingredients: nonspecific psychotherapeutic effect caused by the several assessments carried out during the study, and regression toward the mean.

Age of Onset↗
PubMed1996

Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study.

The effects of citalopram--the most selective serotonin reuptake inhibitor on the market--on psychopathological symptoms were studied in chronic schizophrenic patients on a stable regimen of neuroleptic medication. Outpatients suffering from schizophrenic disorder (DSM-III-R) with Positive and Negative Symptom Scale (PANSS) scores higher than 50 were included in a double-blind placebo-controlled add-on study. The daily dose of citalopram was 20 mg in the first week and 40 mg for the remaining period. A total of 90 patients (45 patients receiving citalopram and 45 receiving placebo) completed the 12-week trial. There were no changes in neuroleptic plasma levels during the trial. There was a significant decrease in total PANNS scores during the trial, although no statistically significant differences between the citalopram group and the placebo group were revealed. The number of responders in terms of severity of illness (CGI) was higher and the increase in subjective well-being (VAS) was greater in patients on citalopram than in those receiving placebo. There were no significant differences in the occurrence of side-effects. It is concluded that, in chronic schizophrenic out-patients, citalopram has no clear effect on the psychopathological symptoms; it may improve the general clinical condition, and it appears to increase the subjective well-being of these patients. Citalopram appears to be safe when used to treat schizophrenic patients who are receiving concomitant neuroleptic treatment.

Adolescent↗
PubMed1995

[Emergency psychiatric treatment of survivors of the Estonia disaster].

The sinking of the car ferry, Estonia, was one of the world's most devastating marine disasters of all time. Mass casualty situations tend to give rise to more mental than physical injuries among the survivors. Psychiatric crisis intervention is in the process of becoming established as one arm in the management of disaster victims. In the article is described the emergency psychiatric care which University Hospital, Abo, was able to offer survivors of the Estonia catastrophe. On the basis of the experience gained, the authors suggest that emergency psychiatric plans should be drawn up at all larger hospitals, as there is no time for careful planning in the event of a major incident.

Crisis Intervention↗
PubMed1992

A suicide epidemic in a psychiatric hospital.

The authors report in detail on an epidemic of six inpatient suicides in a psychiatric hospital in Finland. Suggestion and identification had an effect on the timing as well as on the method of four of the suicides. The epidemic is viewed from individual, network, and organizational perspectives. The authors speculate on how such epidemics could be avoided. An increase in inpatient suicide rates has been reported from many countries, and the Werther effect may thus become a topic of considerable importance in psychiatric hospitals in the future.

Adult↗
PubMedDate not supplied

Impaired Wisconsin card sorting test performance in first-episode schizophrenia: resource or motivation deficit?

Patients with first-episode schizophrenia (n = 27) and age- and education-matched healthy controls (n = 27) were administered the standard version of the Wisconsin Card Sorting Test (WCST), the Wechsler Adult Intelligence Scale-Revised (WAIS-R), and the Rorschach according to the Comprehensive System (CS). Schizophrenic patients achieved a significantly lower full-scale IQ and made more perseverative responses and achieved fewer categories on the WCST than the healthy control group. No significant associations were observed between effort or motivation and WCST performance. Schizophrenic patients who made more perseverative responses tended to be impoverished in terms of available resources, and functioned in a simplistic way when attending to details of the stimulus field. First-episode schizophrenics are able to generate motives and initiate goal-directed activity, but some of them fail to achieve their goals because the cognitive abilities and available resources required for effective planning, purposeful action, or effective performance are impaired.

Adolescent↗
PubMedDate not supplied

Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients.

Steady-state plasma concentrations of commonly used neuroleptic drugs were measured in 90 schizophrenic patients before and after adding placebo or citalopram (40 mg/day) to their treatment regimen. Plasma concentrations of citalopram and its main metabolite, desmethylcitalopram, were also measured. In addition, patients with exceptionally high neuroleptic levels or an increase in adverse effects during the 12-week study period were evaluated for their debrisoquine/sparteine hydroxylase (CYP2D6) genotype, an enzyme responsible for oxidative metabolism of several neuroleptics and selective serotonin re-uptake inhibitors. There were no significant changes in plasma concentrations of haloperidol, chlorpromazine, zuclopenthixol, levomepromazine, thioridazine or perphenazine during the study. Plasma concentrations of citalopram and desmethylcitalopram were well within the levels reported previously with monotherapy, and remained stable throughout the study. None of the 15 patients analysed for the CYP2D6 genotype was a poor metabolizer. It is concluded that clinically important pharmacokinetic drug interactions do not play a crucial role when citalopram is used as an augmentation therapy in neuroleptic-treated schizophrenic patients.

Adult↗